Emmes Group Honoured in EDC PEAK Matrix Assessment for Innovation and Impact

• Emmes Group has been recognised as a Major Contender in the Everest Group’s ‘Life Sciences Electronic Data Capture (EDC) Products PEAK Matrix Assessment 2024 for its Advantage eClinical Cloud platform.

• The platform has supported over 1,200 clinical trials, serving more than 1.1 million patients worldwide.

Emmes Group, a global contract research and technology organisation, has been acknowledged as a Major Contender in the Everest Group’s recently published ‘Life Sciences Electronic Data Capture (EDC) Products PEAK Matrix® Assessment 2024.’ This recognition is attributed to the capabilities of its Advantage eClinical Cloud platform, a unified eClinical platform that combines technology, data, analytics, and AI to enhance clinical research processes.

The Advantage eClinical Cloud platform has powered over 1,200 clinical trials involving more than 1.1 million patients. With adoption by over 32,000 sites and 58,000 users, it is designed to streamline clinical research across sponsors, sites, and patients. The PEAK Matrix® Assessment evaluated 20 platform providers based on market impact, vision, and capability, focusing on technology capabilities, flexibility, and ease of deployment.

Sastry Chilukuri, CEO of Emmes Group, stated, “We’re honoured to be recognised as a major contender by Everest Group. This award is recognition not only of Advantage eClinical Cloud’s capabilities but also the impact it’s had with our customers.” He expressed optimism for the future of the platform as Emmes Group continues to enhance its capabilities with integrated AI.

According to Nisarg Shah, Practice Director at Everest Group, Emmes Group’s unified solution combines various data collection methods, including EDC, eCOA/ePRO, and RTSM, and features therapeutic area-specific libraries and AI-based functionalities. Shah noted that these strengths, along with Emmes Group’s extensive experience in clinical research, have established the company as a key player in the EDC landscape.

Rama Kondru, CEO of Veridix AI, also emphasised the platform’s innovative approach, stating, “At the forefront of clinical technology, our unified platform is redefining the EDC segment.” The emphasis on streamlined data transformations and accelerated insights empowers clients to make rapid, data-driven decisions throughout the clinical trial process.